Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

Dolladille, Charles; Éderhy, Stéphane; Sassier, Marion; Cautela, Jennifer; Thuny, Franck; Cohen, Ariel; Fédrizzi, Sophie; Chrétien, Basile; Da Silva, Angélique; Plane, Anne‐Flore; Legallois, Damien; U. Milliez, Paul; Lelong‐Boulouard, Véronique; Alexandre, Joachim

doi:10.1001/jamaoncol.2020.0726

Public

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

Published in JAMA Oncology • Apr 16, 2020

Authors:

Charles Dolladille

Stéphane Éderhy

Marion Sassier

Abstract

Importance: Limited information is available on the safety of a rechallenge with an immune checkpoint inhibitor (ICI) after an immune-related adverse event (irAE). Objective: To identify the recurrence rate of the same irAE that prompted discontinuation of ICI therapy after an ICI rechallenge in pat...

Subject

Medicine

Discontinuation

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!